APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neutropenia Biologic Drug Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Research

Neutropenia Biologic Drug Treatment Industry Research Report 2026

31 December 2025124 pages

Choose your research edition.

Industry ResearchNeutropenia Biologic Drug Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Neutropenia Biologic Drug Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Neutropenia Biologic Drug Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neutropenia Biologic Drug Treatment Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Neutropenia Biologic Drug Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Neutropenia Biologic Drug Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Neutropenia Biologic Drug Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Neutropenia Biologic Drug Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Neutropenia Biologic Drug Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Neutropenia Biologic Drug Treatment include Kyowa Kirin, Teva Pharmaceutical Industries Ltd., Sanofi, Novartis, Pfizer, Baxter International, Amgen, Partner Therapeutics and Myelo Therapeutics GmbH, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Neutropenia Biologic Drug Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Neutropenia Biologic Drug Treatment.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Neutropenia Biologic Drug Treatment Market by Company

Kyowa Kirin

Teva Pharmaceutical Industries Ltd.

Sanofi

Novartis

Pfizer

Baxter International

Amgen

Partner Therapeutics

Myelo Therapeutics GmbH

Enzychem Lifesciences Corporation

Dong-A ST Co.,Ltd.

CVS Health

Cellerant Therapeutics

Neutropenia Biologic Drug Treatment Segment by Type

Filgrastim

Lenograstim

Pegfilgrastim

Sargramostim

Lipegfilgrastim

Neutropenia Biologic Drug Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Neutropenia Biologic Drug Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neutropenia Biologic Drug Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neutropenia Biologic Drug Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neutropenia Biologic Drug Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Neutropenia Biologic Drug Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Neutropenia Biologic Drug Treatment Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2021-2026) Table 7. Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2027-2032) Table 9. Global Neutropenia Biologic Drug Treatment Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2021-2026) Table 11. Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2027-2032) Table 13. Global Neutropenia Biologic Drug Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Neutropenia Biologic Drug Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Neutropenia Biologic Drug Treatment Market Share by Region (2021-2026) Table 16. Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Neutropenia Biologic Drug Treatment Market Share by Region (2027-2032) Table 18. Neutropenia Biologic Drug Treatment Industry Trends Table 19. Neutropenia Biologic Drug Treatment Industry Drivers Table 20. Neutropenia Biologic Drug Treatment Industry Opportunities and Challenges Table 21. Neutropenia Biologic Drug Treatment Market Restraints Table 22. Global Top Neutropenia Biologic Drug Treatment Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Players (2021-2026) Table 24. Global Neutropenia Biologic Drug Treatment Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Neutropenia Biologic Drug Treatment, Headquarters and Area Served Table 26. Global Neutropenia Biologic Drug Treatment Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Neutropenia Biologic Drug Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Neutropenia Biologic Drug Treatment Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032) & (US$ Million) Table 45. Kyowa Kirin Company Information Table 46. Kyowa Kirin Business Overview Table 47. Kyowa Kirin Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 48. Kyowa Kirin Neutropenia Biologic Drug Treatment Product Portfolio Table 49. Kyowa Kirin Recent Developments Table 50. Teva Pharmaceutical Industries Ltd. Company Information Table 51. Teva Pharmaceutical Industries Ltd. Business Overview Table 52. Teva Pharmaceutical Industries Ltd. Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 53. Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Product Portfolio Table 54. Teva Pharmaceutical Industries Ltd. Recent Developments Table 55. Sanofi Company Information Table 56. Sanofi Business Overview Table 57. Sanofi Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 58. Sanofi Neutropenia Biologic Drug Treatment Product Portfolio Table 59. Sanofi Recent Developments Table 60. Novartis Company Information Table 61. Novartis Business Overview Table 62. Novartis Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 63. Novartis Neutropenia Biologic Drug Treatment Product Portfolio Table 64. Novartis Recent Developments Table 65. Pfizer Company Information Table 66. Pfizer Business Overview Table 67. Pfizer Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 68. Pfizer Neutropenia Biologic Drug Treatment Product Portfolio Table 69. Pfizer Recent Developments Table 70. Baxter International Company Information Table 71. Baxter International Business Overview Table 72. Baxter International Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 73. Baxter International Neutropenia Biologic Drug Treatment Product Portfolio Table 74. Baxter International Recent Developments Table 75. Amgen Company Information Table 76. Amgen Business Overview Table 77. Amgen Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 78. Amgen Neutropenia Biologic Drug Treatment Product Portfolio Table 79. Amgen Recent Developments Table 80. Partner Therapeutics Company Information Table 81. Partner Therapeutics Business Overview Table 82. Partner Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 83. Partner Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio Table 84. Partner Therapeutics Recent Developments Table 85. Myelo Therapeutics GmbH Company Information Table 86. Myelo Therapeutics GmbH Business Overview Table 87. Myelo Therapeutics GmbH Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 88. Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Product Portfolio Table 89. Myelo Therapeutics GmbH Recent Developments Table 90. Enzychem Lifesciences Corporation Company Information Table 91. Enzychem Lifesciences Corporation Business Overview Table 92. Enzychem Lifesciences Corporation Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 93. Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product Portfolio Table 94. Enzychem Lifesciences Corporation Recent Developments Table 95. Dong-A ST Co.,Ltd. Company Information Table 96. Dong-A ST Co.,Ltd. Business Overview Table 97. Dong-A ST Co.,Ltd. Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 98. Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Product Portfolio Table 99. Dong-A ST Co.,Ltd. Recent Developments Table 100. CVS Health Company Information Table 101. CVS Health Business Overview Table 102. CVS Health Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 103. CVS Health Neutropenia Biologic Drug Treatment Product Portfolio Table 104. CVS Health Recent Developments Table 105. Cellerant Therapeutics Company Information Table 106. Cellerant Therapeutics Business Overview Table 107. Cellerant Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026) & (US$ Million) Table 108. Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio Table 109. Cellerant Therapeutics Recent Developments Table 110. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Neutropenia Biologic Drug Treatment Product Image Figure 5. Global Neutropenia Biologic Drug Treatment Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Neutropenia Biologic Drug Treatment Market Share by Type: 2025 VS 2032 Figure 7. Filgrastim Product Figure 8. Lenograstim Product Figure 9. Pegfilgrastim Product Figure 10. Sargramostim Product Figure 11. Lipegfilgrastim Product Figure 12. Global Neutropenia Biologic Drug Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Neutropenia Biologic Drug Treatment Market Share by Application: 2025 VS 2032 Figure 14. Hospital Pharmacies Product Figure 15. Online Pharmacies Product Figure 16. Retail Pharmacies Product Figure 17. Global Neutropenia Biologic Drug Treatment Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 18. Global Neutropenia Biologic Drug Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Neutropenia Biologic Drug Treatment Market Share by Region: 2025 VS 2032 Figure 20. Global Neutropenia Biologic Drug Treatment Market Share by Players in 2025 Figure 21. Global Neutropenia Biologic Drug Treatment Manufacturers Established Date Figure 22. Global Top 5 and 10 Neutropenia Biologic Drug Treatment Players Market Share by Revenue in 2025 Figure 23. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 24. North America Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032) Figure 26. United States Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Canada Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. Mexico Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032) Figure 29. Europe Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032) Figure 31. Germany Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. France Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. U.K. Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Italy Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Spain Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Russia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Netherlands Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Nordic Countries Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032) Figure 41. China Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. Japan Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. South Korea Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. India Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. India Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032) Figure 46. Australia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. China Taiwan Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. Southeast Asia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. South America Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. South America Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032) Figure 51. Brazil Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Argentina Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Chile Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Colombia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 55. Peru Neutropenia Biologic Drug Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 56. Kyowa Kirin Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026) Figure 57. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026) Figure 58. Sanofi Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026) Figure 59. Novartis Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026) Figure 60. Pfizer Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026) Figure 61. Baxter International Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026) Figure 62. Amgen Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026) Figure 63. Partner Therapeutics Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026) Figure 64. Myelo Therapeutics GmbH Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026) Figure 65. Enzychem Lifesciences Corporation Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026) Figure 66. Dong-A ST Co.,Ltd. Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026) Figure 67. CVS Health Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026) Figure 68. Cellerant Therapeutics Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2021-2026)

Scope & coverage.

Types
  • Filgrastim
  • Lenograstim
  • Pegfilgrastim
  • Sargramostim
  • Lipegfilgrastim
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Kyowa Kirin
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis
  • Pfizer
  • Baxter International
  • Amgen
  • Partner Therapeutics
  • Myelo Therapeutics GmbH
  • Enzychem Lifesciences Corporation
  • Dong-A ST Co.,Ltd.
  • CVS Health
  • Cellerant Therapeutics

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Neutropenia Biologic Drug Treatment by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Filgrastim
  5. 2.2.3 Lenograstim
  6. 2.2.4 Pegfilgrastim
  7. 2.2.5 Sargramostim
  8. 2.2.6 Lipegfilgrastim
  9. 2.3 Neutropenia Biologic Drug Treatment by Application
  10. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  11. 2.3.2 Hospital Pharmacies
  12. 2.3.3 Online Pharmacies
  13. 2.3.4 Retail Pharmacies
  14. 2.4 Assumptions and Limitations
3 Neutropenia Biologic Drug Treatment Breakdown Data by Type
  1. 3.1 Global Neutropenia Biologic Drug Treatment Historic Market Size by Type (2021-2026)
  2. 3.2 Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Type (2027-2032)
4 Neutropenia Biologic Drug Treatment Breakdown Data by Application
  1. 4.1 Global Neutropenia Biologic Drug Treatment Historic Market Size by Application (2021-2026)
  2. 4.2 Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Neutropenia Biologic Drug Treatment Market Perspective (2021-2032)
  2. 5.2 Global Neutropenia Biologic Drug Treatment Growth Trends by Region
  3. 5.2.1 Global Neutropenia Biologic Drug Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Neutropenia Biologic Drug Treatment Historic Market Size by Region (2021-2026)
  5. 5.2.3 Neutropenia Biologic Drug Treatment Forecasted Market Size by Region (2027-2032)
  6. 5.3 Neutropenia Biologic Drug Treatment Market Dynamics
  7. 5.3.1 Neutropenia Biologic Drug Treatment Industry Trends
  8. 5.3.2 Neutropenia Biologic Drug Treatment Market Drivers
  9. 5.3.3 Neutropenia Biologic Drug Treatment Market Challenges
  10. 5.3.4 Neutropenia Biologic Drug Treatment Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Neutropenia Biologic Drug Treatment Players by Revenue
  2. 6.1.1 Global Top Neutropenia Biologic Drug Treatment Players by Revenue (2021-2026)
  3. 6.1.2 Global Neutropenia Biologic Drug Treatment Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Neutropenia Biologic Drug Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Neutropenia Biologic Drug Treatment Head Office and Area Served
  6. 6.4 Global Neutropenia Biologic Drug Treatment Players, Product Type & Application
  7. 6.5 Global Neutropenia Biologic Drug Treatment Manufacturers Established Date
  8. 6.6 Global Neutropenia Biologic Drug Treatment Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Neutropenia Biologic Drug Treatment Market Size (2021-2032)
  2. 7.2 North America Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026)
  4. 7.4 North America Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Neutropenia Biologic Drug Treatment Market Size (2021-2032)
  2. 8.2 Europe Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026)
  4. 8.4 Europe Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size (2021-2032)
  2. 9.2 Asia-Pacific Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Neutropenia Biologic Drug Treatment Market Size (2021-2032)
  2. 10.2 South America Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026)
  4. 10.4 South America Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size (2021-2032)
  2. 11.2 Middle East & Africa Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Kyowa Kirin
  2. 12.1.1 Kyowa Kirin Company Information
  3. 12.1.2 Kyowa Kirin Business Overview
  4. 12.1.3 Kyowa Kirin Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  5. 12.1.4 Kyowa Kirin Neutropenia Biologic Drug Treatment Product Portfolio
  6. 12.1.5 Kyowa Kirin Recent Developments
  7. 12.2 Teva Pharmaceutical Industries Ltd.
  8. 12.2.1 Teva Pharmaceutical Industries Ltd. Company Information
  9. 12.2.2 Teva Pharmaceutical Industries Ltd. Business Overview
  10. 12.2.3 Teva Pharmaceutical Industries Ltd. Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  11. 12.2.4 Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Product Portfolio
  12. 12.2.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  13. 12.3 Sanofi
  14. 12.3.1 Sanofi Company Information
  15. 12.3.2 Sanofi Business Overview
  16. 12.3.3 Sanofi Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  17. 12.3.4 Sanofi Neutropenia Biologic Drug Treatment Product Portfolio
  18. 12.3.5 Sanofi Recent Developments
  19. 12.4 Novartis
  20. 12.4.1 Novartis Company Information
  21. 12.4.2 Novartis Business Overview
  22. 12.4.3 Novartis Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  23. 12.4.4 Novartis Neutropenia Biologic Drug Treatment Product Portfolio
  24. 12.4.5 Novartis Recent Developments
  25. 12.5 Pfizer
  26. 12.5.1 Pfizer Company Information
  27. 12.5.2 Pfizer Business Overview
  28. 12.5.3 Pfizer Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  29. 12.5.4 Pfizer Neutropenia Biologic Drug Treatment Product Portfolio
  30. 12.5.5 Pfizer Recent Developments
  31. 12.6 Baxter International
  32. 12.6.1 Baxter International Company Information
  33. 12.6.2 Baxter International Business Overview
  34. 12.6.3 Baxter International Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  35. 12.6.4 Baxter International Neutropenia Biologic Drug Treatment Product Portfolio
  36. 12.6.5 Baxter International Recent Developments
  37. 12.7 Amgen
  38. 12.7.1 Amgen Company Information
  39. 12.7.2 Amgen Business Overview
  40. 12.7.3 Amgen Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  41. 12.7.4 Amgen Neutropenia Biologic Drug Treatment Product Portfolio
  42. 12.7.5 Amgen Recent Developments
  43. 12.8 Partner Therapeutics
  44. 12.8.1 Partner Therapeutics Company Information
  45. 12.8.2 Partner Therapeutics Business Overview
  46. 12.8.3 Partner Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  47. 12.8.4 Partner Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio
  48. 12.8.5 Partner Therapeutics Recent Developments
  49. 12.9 Myelo Therapeutics GmbH
  50. 12.9.1 Myelo Therapeutics GmbH Company Information
  51. 12.9.2 Myelo Therapeutics GmbH Business Overview
  52. 12.9.3 Myelo Therapeutics GmbH Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  53. 12.9.4 Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Product Portfolio
  54. 12.9.5 Myelo Therapeutics GmbH Recent Developments
  55. 12.10 Enzychem Lifesciences Corporation
  56. 12.10.1 Enzychem Lifesciences Corporation Company Information
  57. 12.10.2 Enzychem Lifesciences Corporation Business Overview
  58. 12.10.3 Enzychem Lifesciences Corporation Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  59. 12.10.4 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product Portfolio
  60. 12.10.5 Enzychem Lifesciences Corporation Recent Developments
  61. 12.11 Dong-A ST Co.,Ltd.
  62. 12.11.1 Dong-A ST Co.,Ltd. Company Information
  63. 12.11.2 Dong-A ST Co.,Ltd. Business Overview
  64. 12.11.3 Dong-A ST Co.,Ltd. Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  65. 12.11.4 Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Product Portfolio
  66. 12.11.5 Dong-A ST Co.,Ltd. Recent Developments
  67. 12.12 CVS Health
  68. 12.12.1 CVS Health Company Information
  69. 12.12.2 CVS Health Business Overview
  70. 12.12.3 CVS Health Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  71. 12.12.4 CVS Health Neutropenia Biologic Drug Treatment Product Portfolio
  72. 12.12.5 CVS Health Recent Developments
  73. 12.13 Cellerant Therapeutics
  74. 12.13.1 Cellerant Therapeutics Company Information
  75. 12.13.2 Cellerant Therapeutics Business Overview
  76. 12.13.3 Cellerant Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2021-2026)
  77. 12.13.4 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio
  78. 12.13.5 Cellerant Therapeutics Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst